Melatonin and its metabolites have been demonstrated to modulate the
glucose,
dyslipidemia and other metabolic disorders. This study aimed to explore a novel mechanism responsible for
diabetic cardiomyopathy development, and also validated whether
melatonin played a protective role in repairing damaged heart in the diabetes setting. Our data demonstrated that
spleen tyrosine kinase (Syk) was activated by chronic high-
glucose stimulus and contributed to the development of
diabetic cardiomyopathy. However, genetic ablation of Syk or supplementation of
melatonin to inhibit Syk activation improved diabetic myocardial function, reduced cardiac
fibrosis and preserved cardiomyocytes viability. Mechanistically, activated Syk repressed the expression and activity of mitochondrial complex I (COX-1), unfortunately evoking mitochondrial and/or cellular ROS overproduction. Subsequently, excessive
superoxide facilitated SERCA peroxidation which failed to re-uptake the cytoplasmic
calcium back into endoplasmic reticulum (ER), leading to cellular
calcium overload. Finally, activated oxidative stress and
calcium overload collectively promoted the high-
glucose-induced cardiomyocytes death via caspase-9-related mitochondrial apoptosis and caspase-12-involved ER apoptosis, respectively. Interestingly, inhibition of Syk via Syk genetic ablation or
melatonin administration blocked Syk/COX-1/SERCA signalling pathways, and thus abolished mitochondrial- and ER-mediated cardiomyocyte death in the setting of diabetes. Based on these results, we suggest a novel pathway by which high-
glucose stimulus induces
diabetic cardiomyopathy is possibly through an activation of Syk/COX-1/SERCA axis which could be abrogated by
melatonin treatment.